UNSPSC 51372037: Morphine sulfate anhydrous

This classification denotes an opiate with the molecular formula 2C17H19NO3.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DY70C97N30, chemically known as morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl, (5.alpha.,6.alpha.)-, sulfate (2:1) (salt), but more generally known as morphine sulfate anhydrous, which bears US NIH Compound Identifier 5359250. European Medicines Agency schedules morphine sulfate anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03332MIG.

UNSPSC 51372037 Morphine sulfate anhydrous is a Commodity code that covers pharmaceutical active pharmaceutical ingredients and finished pharmaceutical products, though recent state and local solicitations tagged to this code reflect a broader scope: naloxone distribution for overdose reversal, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical supply contracts. State and local governments procuring under or near this code seek manufacturers and distributors of prescription pharmaceuticals, controlled substances, and over-the-counter products for delivery through health departments, pharmacy benefit programs, and cooperative purchasing consortia. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota MMCAP serving member states including Oregon). These entities prioritize compliance with FDA manufacturing standards, Drug Supply Chain Security Act (DSCSA) certification, cGMP requirements, and integration with authorized pharmaceutical wholesalers.

Recent activity spans Florida, Texas, and the MMCAP multistate consortium. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a July 26, 2023 response deadline—a competitive invitation for bids requiring electronic submission through the county's e-Procurement Portal, E-Verify compliance, and workers' compensation and general liability insurance. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 to solicit vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information about direct contracting capacity, net pricing flexibility, and value-based agreement implementation without formal competitive timelines or award amounts at that stage. The Minnesota Department of Administration's MMCAP posted an RFP (S1070000015802) on January 20, 2026 with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products, requiring vendors to maintain relationships with authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), submit NDC and pricing data in CSV format, carry $5 million commercial general liability insurance, and accept a 3 percent administrative fee on contract purchases.